These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 10506635)
1. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. Galanis E; Hersh EM; Stopeck AT; Gonzalez R; Burch P; Spier C; Akporiaye ET; Rinehart JJ; Edmonson J; Sobol RE; Forscher C; Sondak VK; Lewis BD; Unger EC; O'Driscoll M; Selk L; Rubin J J Clin Oncol; 1999 Oct; 17(10):3313-23. PubMed ID: 10506635 [TBL] [Abstract][Full Text] [Related]
2. Intratumoral administration of a 1,2-dimyristyloxypropyl-3- dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. Galanis E; Burch PA; Richardson RL; Lewis B; Pitot HC; Frytak S; Spier C; Akporiaye ET; Peethambaram PP; Kaur JS; Okuno SH; Unni KK; Rubin J Cancer; 2004 Dec; 101(11):2557-66. PubMed ID: 15517589 [TBL] [Abstract][Full Text] [Related]
3. Intratumoral interleukin 2 for renal-cell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid complex. Hoffman DM; Figlin RA World J Urol; 2000 Apr; 18(2):152-6. PubMed ID: 10854152 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. Daniels GA; Galanis E Curr Opin Mol Ther; 2001 Feb; 3(1):70-6. PubMed ID: 11249734 [TBL] [Abstract][Full Text] [Related]
6. Leuvectin Vical Inc. Kaushik A Curr Opin Investig Drugs; 2001 Jul; 2(7):976-81. PubMed ID: 11757801 [TBL] [Abstract][Full Text] [Related]
7. Studies of direct intratumoral gene transfer using cationic lipid-complexed plasmid DNA. Clark PR; Stopeck AT; Ferrari M; Parker SE; Hersh EM Cancer Gene Ther; 2000 Jun; 7(6):853-60. PubMed ID: 10880015 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. Stopeck AT; Hersh EM; Akporiaye ET; Harris DT; Grogan T; Unger E; Warneke J; Schluter SF; Stahl S J Clin Oncol; 1997 Jan; 15(1):341-9. PubMed ID: 8996161 [TBL] [Abstract][Full Text] [Related]
9. Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. Thompson JA; Curti BD; Redman BG; Bhatia S; Weber JS; Agarwala SS; Sievers EL; Hughes SD; DeVries TA; Hausman DF J Clin Oncol; 2008 Apr; 26(12):2034-9. PubMed ID: 18347008 [TBL] [Abstract][Full Text] [Related]
10. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/beta2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Stopeck AT; Jones A; Hersh EM; Thompson JA; Finucane DM; Gutheil JC; Gonzalez R Clin Cancer Res; 2001 Aug; 7(8):2285-91. PubMed ID: 11489803 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of established tumors in mice by intratumoral injection of interleukin-2 plasmid DNA: induction of CD8+ T-cell immunity. Saffran DC; Horton HM; Yankauckas MA; Anderson D; Barnhart KM; Abai AM; Hobart P; Manthorpe M; Norman JA; Parker SE Cancer Gene Ther; 1998; 5(5):321-30. PubMed ID: 9824052 [TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534 [TBL] [Abstract][Full Text] [Related]
13. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Belldegrun A; Tso CL; Zisman A; Naitoh J; Said J; Pantuck AJ; Hinkel A; deKernion J; Figlin R Hum Gene Ther; 2001 May; 12(8):883-92. PubMed ID: 11387054 [TBL] [Abstract][Full Text] [Related]
14. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603 [TBL] [Abstract][Full Text] [Related]
15. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon. Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820 [TBL] [Abstract][Full Text] [Related]
16. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma. Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357 [TBL] [Abstract][Full Text] [Related]
17. Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma. Bulgarelli J; Piccinini C; Petracci E; Pancisi E; Granato AM; de Rosa F; Guidoboni M; Petrini M; Ancarani V; Foschi G; Romeo A; Tontini L; De Giorgi U; Lolli C; Gentili G; Valmorri L; Rossi A; Ferroni F; Casadei C; Cortesi P; Crudi L; Ridolfi L Front Immunol; 2021; 12():778459. PubMed ID: 34777395 [TBL] [Abstract][Full Text] [Related]